RxDoctor Payments Data

Tapeesh Kansal, MD

Psychiatry · San Bernardino, CANPI 1841291408

Payments from drug & device makers

$2,546in general payments, 2019–2025

Across 106 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$730
  • Alkermes, Inc.$647
  • Indivior Inc.$382
  • Johnson & Johnson$217
  • Neurocrine Biosciences, Inc.$200
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • plus $244 from 3 others

What the payments were for

  • Food & beverage$2,43496%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,546 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$29,530
Medicare patients
50
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate139$391,929
Abilify MaintenaAripiprazole56$150,876
LybalviOlanzapine/Samidorphan Malate13$19,721
Aripiprazole OdtAripiprazole17$17,082
Clozapine150$14,116
Clozapine OdtClozapine33$11,954
Risperidone OdtRisperidone43$10,856
Olanzapine OdtOlanzapine58$8,463
Fluphenazine Hcl61$5,801
Divalproex Sodium ErDivalproex Sodium211$5,764
Olanzapine447$5,519
Aripiprazole136$4,356
Haloperidol95$3,239
Quetiapine Fumarate242$2,626
Risperidone161$2,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$217$391,929139 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$71$150,87656 claims
Alkermes, Inc.Lybalvi$647$19,72113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →